Cibacen 5mg Film Coated Tablets

  • Name:

    Cibacen 5mg Film Coated Tablets

  • Company:
    info
  • Active Ingredients:

    Benazepril Hydrochloride

  • Legal Category:

    Product subject to medical prescription which may be renewed (B)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 30/07/18

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 30/7/2018

Click on this link to Download PDF directly

Mylan IRE Healthcare Limited

Mylan IRE Healthcare Limited

Company Products

Medicine NameActive Ingredients
Medicine Name ALDARA 5% CREAM Active Ingredients Imiquimod
Medicine Name Ancotil 2.5g/250ml Solution for Infusion Active Ingredients Flucytosine
Medicine Name Brufen 400mg film-coated Tablets Active Ingredients Ibuprofen
Medicine Name Brufen 600mg film-coated tablets Active Ingredients Ibuprofen
Medicine Name Brufen Paediatric 100mg/5ml Oral Suspension Active Ingredients Ibuprofen
Medicine Name Brufen Retard 800mg prolonged release tablets Active Ingredients Ibuprofen
Medicine Name Calvidin 600mg/400IU Chewable Tablets Active Ingredients Calcium Carbonate, Colecalciferol (Vitamin D3)
Medicine Name Cibacen 10mg Film Coated Tablet Active Ingredients Benazepril Hydrochloride
Medicine Name Cibacen 5mg Film Coated Tablets Active Ingredients Benazepril Hydrochloride
Medicine Name Clozaril 100mg Tablets Active Ingredients Clozapine
Medicine Name Clozaril 25mg Tablets Active Ingredients Clozapine
Medicine Name Colifoam 10% w/w Rectal Foam Active Ingredients Hydrocortisone Acetate
Medicine Name Colofac 135mg Tablets Active Ingredients Mebeverine Hydochloride
Medicine Name Creon 10000 Gastro-resistant Capsules Active Ingredients Pancreatin
Medicine Name Creon 25000 Gastro-resistant Capsules Active Ingredients Pancreatin
Medicine Name Creon for Children 5000 Gastro-resistant Granules Active Ingredients Pancreatin
Medicine Name Cyklokapron 500mg Tablets Active Ingredients Tranexamic Acid
Medicine Name Dalmane 15mg Hard Capsules Active Ingredients Flurazepam monohydrochloride
Medicine Name Dalmane 30mg Hard Capsules Active Ingredients Flurazepam monohydrochloride
Medicine Name Desunin 4000IU Tablets Active Ingredients Colecalciferol (Vitamin D3)
Medicine Name Desunin 800IU Tablets Active Ingredients Colecalciferol (Vitamin D3)
Medicine Name DIFFLAM 3% CREAM Active Ingredients Benzydamine Hydrochloride
Medicine Name DIFFLAM ORAL RINSE Active Ingredients Benzydamine Hydrochloride
Medicine Name DIFFLAM SPRAY Active Ingredients Benzydamine Hydrochloride
Medicine Name Dona 1500mg Powder for Oral Solution Active Ingredients Glucosamine Sulfate, Sodium Chloride
1 - 0 of 95 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 30 July 2018 PIL

Reasons for updating

  • New PIL for new product

Updated on 30 July 2018 SmPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 8 - Marketing authorisation number(s)
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 3 January 2017 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 3 January 2017 SmPC

Reasons for updating

  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

In section 4.5: Information regarding interaction has been added
In section 10: date of revision has changed

Updated on 3 January 2017 PIL

Reasons for updating

  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

In section 4.5: Information regarding interaction has been added
In section 10: date of revision has changed

Updated on 14 October 2016 SmPC

Reasons for updating

  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.9 - Overdose
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

In section 4.4: Information regarding ciclosporin and heparin has been added. Information regarding mTOR inhibitors and NSAIDs has been added.

In section 4.9: Information to overdose has been added.

In section 10: Date of revision changed.

Updated on 14 October 2016 PIL

Reasons for updating

  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.9 - Overdose
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

In section 4.4: Information regarding ciclosporin and heparin has been added. Information regarding mTOR inhibitors and NSAIDs has been added.

In section 4.9: Information to overdose has been added.

In section 10: Date of revision changed.

Updated on 5 January 2015 PIL

Reasons for updating

  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

In section 4.1: Text is added to refer to other sections

In section 4.2: Text is added to refer to other sections. Reference has changed to elderly patients

In section 4.3: Concomitant use with aliskiren-containing products has been added as a contraindication

In section 4.4: Information regarding dual blockade of the renin-angiotensin-aldosterone system has been added

In section 4.5: Information regarding clinical trial data and dual blockade of the renin-angiotensin-aldosterone system has been added

In section 4.8: Statement regarding adverse reporting has been added

In section 5.1: Text regarding particular clinical trials ONTARGET and  VA NEPHRON-D has been added. Information regarding ALTITUDE study has been added.

In section 10: date of revision has changed

Updated on 5 January 2015 SmPC

Reasons for updating

  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

In section 4.1: Text is added to refer to other sections

In section 4.2: Text is added to refer to other sections. Reference has changed to elderly patients

In section 4.3: Concomitant use with aliskiren-containing products has been added as a contraindication

In section 4.4: Information regarding dual blockade of the renin-angiotensin-aldosterone system has been added

In section 4.5: Information regarding clinical trial data and dual blockade of the renin-angiotensin-aldosterone system has been added

In section 4.8: Statement regarding adverse reporting has been added

In section 5.1: Text regarding particular clinical trials ONTARGET and  VA NEPHRON-D has been added. Information regarding ALTITUDE study has been added.

In section 10: date of revision has changed

Updated on 30 January 2013 PIL

Reasons for updating

  • Change to section 6.3 - Shelf life
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

In section 6.3: the shelf-life has been reduced from 3 years to 2 years
In section 10: the date of revision has changed to January 2013

Updated on 30 January 2013 SmPC

Reasons for updating

  • Change to section 6.3 - Shelf life
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

In section 6.3: the shelf-life has been reduced from 3 years to 2 years
In section 10: the date of revision has changed to January 2013

Updated on 4 December 2012 PIL

Reasons for updating

  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text
  • Change to section 4.4 - Special warnings and precautions for use

Free text change information supplied by the pharmaceutical company

·         In section 4.4: a short warning regarding angioedema has been added

·         In section 4.5: an additional warning regarding the interaction of gold has been added

·         In section 4.8: there has been several changes made to the undesirable effects

·         In section 5.1: an additional statement has been added relating to the use of Cibacen in CHF patients

·         In section 10: the date of revision has been changed to November 2012

Updated on 4 December 2012 SmPC

Reasons for updating

  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text
  • Change to section 4.4 - Special warnings and precautions for use

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

·         In section 4.4: a short warning regarding angioedema has been added

·         In section 4.5: an additional warning regarding the interaction of gold has been added

·         In section 4.8: there has been several changes made to the undesirable effects

·         In section 5.1: an additional statement has been added relating to the use of Cibacen in CHF patients

·         In section 10: the date of revision has been changed to November 2012

Updated on 2 November 2011 PIL

Reasons for updating

  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

In section 4.3; Additional information regarding contradindications have been added
In section 4.4; warnings against the use of ACE inhibitors in pregnancy have been added
In section 4.6; the section has been restructed to include ACE inhibitor warnings in pregnancy and lactation
In section 5.2; additional information regarding lactation has been added
In section 10; the date of revision has changed

Updated on 2 November 2011 SmPC

Reasons for updating

  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

In section 4.3; Additional information regarding contradindications have been added
In section 4.4; warnings against the use of ACE inhibitors in pregnancy have been added
In section 4.6; the section has been restructed to include ACE inhibitor warnings in pregnancy and lactation
In section 5.2; additional information regarding lactation has been added
In section 10; the date of revision has changed

Updated on 18 March 2011 PIL

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

In section 7: the address of the MAH has changed
In section 10: the date of revision has changed to March 2011

Updated on 18 March 2011 SmPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

In section 7: the address of the MAH has changed
In section 10: the date of revision has changed to March 2011

Updated on 20 April 2009 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 5.3 - Preclinical safety data
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 2: Small text change
Section 3: Change in description of tablet
Section 4.2: Paediatric information added
Section 4.5: Minor text correction
Section 4.8: additional Information
Section 4.9: Correction of text
Section 5.1: Additional information
Section 5.2:  Additiona paediatric information
Section 5.3:  Additional information
Section 9: Change of format
Section 10: Change of date of revision
 

Updated on 20 April 2009 PIL

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 5.3 - Preclinical safety data
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

Section 2: Small text change
Section 3: Change in description of tablet
Section 4.2: Paediatric information added
Section 4.5: Minor text correction
Section 4.8: additional Information
Section 4.9: Correction of text
Section 5.1: Additional information
Section 5.2:  Additiona paediatric information
Section 5.3:  Additional information
Section 9: Change of format
Section 10: Change of date of revision
 

Updated on 4 October 2007 PIL

Reasons for updating

  • Change to marketing authorisation holder

Free text change information supplied by the pharmaceutical company

MAH change from

Novartis Pharmaceuticals UK Limited

Frimley Business Park

Frimley

Camberley

Surrey

GU16 7SR

UK
 
to
 

Meda Health Sales Ireland Ltd

Office 10, Dunboyne Business Park

Dunboyne

Co. Meath
 
PA number changed from
PA 13/78/1
to
PA 1332/1/1
 
 
 
 

Updated on 4 October 2007 SmPC

Reasons for updating

  • Change to marketing authorisation holder

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

MAH change from

Novartis Pharmaceuticals UK Limited

Frimley Business Park

Frimley

Camberley

Surrey

GU16 7SR

UK
 
to
 

Meda Health Sales Ireland Ltd

Office 10, Dunboyne Business Park

Dunboyne

Co. Meath
 
PA number changed from
PA 13/78/1
to
PA 1332/1/1
 
 
 
 

Updated on 5 August 2005 SmPC

Reasons for updating

  • Change to section 6.1 - List of excipients

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 5 August 2005 PIL

Reasons for updating

  • Change to section 6.1 - List of excipients

Updated on 4 February 2005 SmPC

Reasons for updating

  • New SPC for medicines.ie

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 4 February 2005 PIL

Reasons for updating

  • New SPC for medicines.ie